Time to Buy Boston Scientific Corporation After Today’s Option Traders Bet?

 Time to Buy Boston Scientific Corporation After Today's Option Traders Bet?

In today’s session Boston Scientific Corporation (BSX) registered an unusually high (264) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the May, 2017 call, expecting serious BSX increase. With 264 contracts traded and 7134 open interest for the May, 17 contract, it seems this is a quite bullish bet. The option with symbol: BSX170519C00024000 closed last at: $0.54 or 3.8% up. About 3.85 million shares traded hands. Boston Scientific Corporation (NYSE:BSX) has risen 7.14% since April 25, 2016 and is uptrending. It has outperformed by 1.13% the S&P500.

Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on February, 2. They expect $0.28 earnings per share, up 7.69% or $0.02 from last year’s $0.26 per share. BSX’s profit will be $384.30M for 18.63 P/E if the $0.28 EPS becomes a reality. After $0.27 actual earnings per share reported by Boston Scientific Corporation for the previous quarter, Wall Street now forecasts 3.70% EPS growth.

Boston Scientific Corporation (NYSE:BSX) Ratings Coverage

Out of 22 analysts covering Boston Scientific Corporation (NYSE:BSX), 17 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 77% are positive. Boston Scientific Corporation has been the topic of 29 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The rating was initiated by Guggenheim with “Buy” on Thursday, June 9. Goldman Sachs upgraded the stock to “Neutral” rating in Thursday, August 27 report. The stock of Boston Scientific Corporation (NYSE:BSX) has “Outperform” rating given on Monday, August 10 by Credit Suisse. The stock has “Buy” rating given by Argus Research on Thursday, September 1. As per Thursday, February 25, the company rating was initiated by Suntrust Robinson. The company was maintained on Friday, July 29 by Needham. The company was maintained on Friday, July 29 by Jefferies. Stifel Nicolaus maintained Boston Scientific Corporation (NYSE:BSX) on Thursday, April 28 with “Buy” rating. The firm has “Strong Buy” rating by Raymond James given on Monday, October 5. Wedbush maintained the shares of BSX in a report on Friday, July 29 with “Neutral” rating.

According to Zacks Investment Research, “Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of minimally invasive medical devices. The company’s products are used in a broad range of interventional medical specialties, including cardiology, electrophysiology, gastroenterology, neuro-endovascular therapy, pulmonary medicine, radiology, urology and vascular surgery.”

Insitutional Activity: The institutional sentiment decreased to 1.12 in Q2 2016. Its down 0.04, from 1.16 in 2016Q1. The ratio worsened, as 25 funds sold all Boston Scientific Corporation shares owned while 168 reduced positions. 63 funds bought stakes while 160 increased positions. They now own 1.23 billion shares or 2.15% less from 1.26 billion shares in 2016Q1.
Piershale Group accumulated 0% or 100 shares. Lpl Fincl Limited Liability Company last reported 107,516 shares in the company. Regions Fincl Corp owns 56,002 shares or 0.02% of their US portfolio. The Montana-based Da Davidson Communication has invested 0% in Boston Scientific Corporation (NYSE:BSX). The Illinois-based Hightower Advsr Ltd Limited Liability Company has invested 0% in Boston Scientific Corporation (NYSE:BSX). Atika Capital Mgmt Ltd Com holds 0.64% or 64,000 shares in its portfolio. Moreover, Carroll Financial Associate has 0.01% invested in Boston Scientific Corporation (NYSE:BSX) for 2,500 shares. Cambridge Inv Research Advsr Incorporated holds 45,468 shares or 0.02% of its portfolio. Chevy Chase Inc reported 1.16M shares or 0.15% of all its holdings. Airain reported 191,536 shares or 0.26% of all its holdings. Kistler has 317 shares for 0% of their US portfolio. Creative Planning has invested 0% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Ghost Tree Cap Ltd Limited Liability Company has invested 2.19% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Public Employees Retirement Association Of Colorado has 0.06% invested in the company for 288,418 shares. North Star accumulated 480 shares or 0% of the stock.

Insider Transactions: Since June 1, 2016, the stock had 0 insider buys, and 8 insider sales for $5.11 million net activity. Another trade for 100,000 shares valued at $2.27M was made by Mahoney Michael F on Wednesday, June 1. Pratt Timothy A. sold $541,826 worth of stock. Shares for $59,750 were sold by Sorenson John Bradley. Another trade for 2,480 shares valued at $59,594 was sold by Pierce David A. Ballinger Kevin J. also sold $1.88M worth of Boston Scientific Corporation (NYSE:BSX) shares. Phalen Michael P. had sold 35,000 shares worth $841,050.

Boston Scientific Corporation is a developer, maker and marketer of medical devices that are used in a range of interventional medical specialties. The company has a market cap of $28.63 billion. The Firm offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions , Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It has a 365.9 P/E ratio. It operates in three divisions: Cardiovascular, Rhythm Management and MedSurg.

BSX Company Profile

Boston Scientific Corporation, incorporated on June 22, 1979, is a developer, maker and marketer of medical devices that are used in a range of interventional medical specialties. The Firm offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. The Firm operates through three divisions: Cardiovascular, Rhythm Management and MedSurg. The Company’s Cardiovascular segment consists of Interventional Cardiology and PI businesses. The Company’s Rhythm Management segment consists of CRM and EP businesses. The Company’s MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses.

More important recent Boston Scientific Corporation (NYSE:BSX) news were published by: Prnewswire.com which released: “Boston Scientific To Participate In Citi 2016 Global Healthcare Conference” on November 23, 2016, also Prnewswire.com published article titled: “Boston Scientific Acquires Resectrâ„¢ Tissue Resection Device from Distal …”, Prnewswire.com published: “Boston Scientific To Participate In Piper Jaffray 2016 Healthcare Conference” on November 16, 2016. More interesting news about Boston Scientific Corporation (NYSE:BSX) was released by: Streetinsider.com and their article: “Boston Scientific (BSX) Announces C Losing of $210 EndoChoice (GI) Acquisition” with publication date: November 22, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment